• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The COVID-19 virus mutated to outsmart key antibody treatments. Better ones are coming
In 2020, as the COVID-19 pandemic raged and other effective drugs were elusive, monoclonal antibodies (mAbs) emerged as a lifesaving treatment. But now, 3 years later, all the approvals for COVID-19–fighting antibodies have been rescinded in the United States, as mutations of the SARS-CoV-2 virus have left the drugs—which target parts of the original virus—ineffective. Researchers around the globe are now trying to revive antibody treatments by redesigning them to take aim at targets that are less prone to mutation. “There are new approaches that present a much more challenging task for the virus to evade,” ...
Source: ScienceNOW - May 24, 2023 Category: Science Source Type: news

Uncovering the information immunology journals transmitted for COVID-19: A bibliometric and visualization analysis
ConclusionThis study systematically uncovered a holistic picture of the current research on COVID-19 published in major immunology journals from the perspective of bibliometrics, which will provide a reference for future research in this field.
Source: Frontiers in Immunology - October 31, 2022 Category: Allergy & Immunology Source Type: research

Risk Factors for Olfactory and Gustatory Dysfunctions in Patients with SARS-CoV-2 Infection
Conclusion: Our study indicates that current smoking and history of allergy (particularly respiratory) significantly increase the risk for smell loss in COVID-19 patients; the latter is also significantly associated to taste loss. Hospitalization has an inverse association with the risk of olfactory and gustatory dysfunctions, suggesting that these may be symptoms characteristics of less severe SARS-CoV-2 infection.Neuroepidemiology
Source: Neuroepidemiology - April 1, 2021 Category: Epidemiology Source Type: research

SARS-CoV2 infection in those on Mepolizumab therapy
Coronavirus disease 2019 (COVID ‐19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 1, continues to cause morbidity and mortality across the world. Expert recommendation is to continue biologic therapy unchanged in severe eosinophilic asthma 2,3 but concern has been expressed as eosinopenia may be a risk factor for worse disease outcomes 4. Here we report the outcomes of four patients from centres in the UK, Italy and North America with COVID-19, whilst receiving treatment with mepolizumab, an anti IL-5 monoclonal antibody, which reduces eosinophils to within the normal range 5.
Source: Annals of Allergy, Asthma and Immunology - January 12, 2021 Category: Allergy & Immunology Authors: Adnan Azim, Laura Pini, Zeeshan Khakwani, Santosh Kumar, Peter Howarth Tags: Letters Source Type: research

Severe acute respiratory syndrome coronavirus 2 infection in those on mepolizumab therapy
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),1 continues to cause morbidity and mortality across the world. The expert recommendation is to continue biologic therapy unchanged in severe eosinophilic asthma2,3 but concern has been expressed as eosinopenia may be a risk factor for worse disease outcomes.4,5 Here, we report the outcomes of 4 patients from centers in the United Kingdom, Italy, and North America with COVID-19, while receiving treatment with mepolizumab, an anti –interleukin 5 monoclonal antibody, which reduces eosinophils to within the reference range.
Source: Annals of Allergy, Asthma and Immunology - January 12, 2021 Category: Allergy & Immunology Authors: Adnan Azim, Laura Pini, Zeeshan Khakwani, Santosh Kumar, Peter Howarth Tags: Letters Source Type: research

The Great Vaccine Race: Inside the Unprecedented Scramble to Immunize the World Against COVID-19
The cleverest of enemies thrive on surprise attacks. Viruses—and coronaviruses in particular—know this well. Remaining hidden in animal hosts for decades, they mutate steadily, sometimes serendipitously morphing into more effective and efficient infectious agents. When a strain with just the right combination of genetic codes that spell trouble for people makes the leap from animal to human, the ambush begins. Such was the case with SARS-CoV-2, the coronavirus behind COVID-19, and the attack was mostly silent and insidious at first. Many people infected with SARS-CoV-2 remained oblivious as they served as the v...
Source: TIME: Health - September 10, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Magazine Source Type: news

Authors' response
We thank Ciprandi et  al1 for their salient points related to our recent article and description of their experiences with Italian patients.2 As they pointed out, children and those with allergy and asthma seem to be at a lower risk of coronavirus disease 2019 (COVID-19) and have milder disease.3,4 Recently, however, a severe complication called multisystem inflammatory syndrome in children, which appears to be associated with COVID-19, has been described in pediatric patients.5 The incidence of this Kawasaki disease–like condition, its causes, and optimal management are still under investigation.
Source: Annals of Allergy, Asthma and Immunology - August 26, 2020 Category: Allergy & Immunology Authors: Ayobami T. Akenroye, Robert Wood, Corinne Keet Tags: Correspondence Source Type: research

Children and adolescents with allergy and/or asthma seem to be protected from coronavirus disease 2019
Akenroye et  al1 discussed the use of corticosteroids and biologics in asthma during coronavirus disease 2019 (COVID-19) pandemic. COVID-19 began in the People's Republic of China and rapidly spread worldwide.2 Italy was the first European country involved in the pandemic and the first cluster occurring in Sou th Lombardy. The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), penetrates the host cells binding to the angiotensin-converting enzyme 2 (ACE2) receptors.
Source: Annals of Allergy, Asthma and Immunology - August 26, 2020 Category: Allergy & Immunology Authors: Giorgio Ciprandi, Amelia Licari, Gaetana Filippelli, Maria Angela Tosca, Gian Luigi Marseglia Tags: Correspondence Source Type: research

Why the U.S. Is Losing the War On COVID-19
It is a frightening time to live in the United States. COVID-19, a novel disease as ruthless as it is seemingly random, is picking us off by the thousands; even many of those who “recover” may never truly be the same again. The pandemic has exposed the gulf between what this country promises for its citizens and what it actually delivers. And as the U.S. barrels toward Election Day, the outbreak is sure to complicate the voting process, with potentially disastrous results. For a short time in the spring, it appeared the U.S. was getting a grip on its outbreak. Hard-hit states like New York successfully flattene...
Source: TIME: Science - August 13, 2020 Category: Science Authors: Alex Fitzpatrick Tags: Uncategorized COVID-19 UnitedWeRise20Disaster Source Type: news

Clinical course and outcomes of patients with asthma hospitalized for severe acute respiratory syndrome coronavirus 2 pneumonia
Pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly recognized illness that has spread rapidly from Wuhan to other provinces in the People's Republic of China and around the world. Italy was one of the most affected countries. From February 2020, Lombardy (northern Italy) was the most affected region by the coronavirus disease 2019 (COVID-19) infection, with a total number of 93,990 positive cases and a total number of 16,302 deaths (data as of July 2, 2020).
Source: Annals of Allergy, Asthma and Immunology - July 30, 2020 Category: Allergy & Immunology Authors: Carlo Lombardi, Elena Roca, Barbara Bigni, Marcello Cottini, Giovanni Passalacqua Tags: Letters Source Type: research

Smell loss is a prognostic factor for lower severity of COVID-19
Coronavirus disease 2019 (COVID-19) can present with a myriad of symptoms.1 Guidelines from China, the United Kingdom and Italy had focused screening efforts on patients with fever and cough, excluding anosmia from similar scrutiny.1 However, screening of individuals with reported anosmia and dysgeusia has been associated with a greater likelihood of a positive COVID-19 result than other indicator of an upper respiratory infection.2-4 The relative predictive value of presenting COVID-19 symptoms is under current investigation.
Source: Annals of Allergy, Asthma and Immunology - July 23, 2020 Category: Allergy & Immunology Authors: Katharine J. Foster, Emilio Jauregui, Bobby Tajudeen, Faraz Bishehsari, Mahboobeh Mahdavinia Tags: Letters Source Type: research

Smell loss is a prognostic factor for lower severity of coronavirus disease 2019
Coronavirus disease 2019 (COVID-19) can present with a myriad of symptoms.1 Guidelines from the People's Republic of China, the United Kingdom, and Italy had focused screening efforts on patients with fever and cough, excluding anosmia from similar scrutiny.1 However, the screening of individuals with reported anosmia and dysgeusia has been associated with a greater likelihood of a positive COVID-19 result than other indicators of an upper respiratory tract infection.2-4 The relative predictive value of presenting COVID-19 symptoms is under current investigation.
Source: Annals of Allergy, Asthma and Immunology - July 23, 2020 Category: Allergy & Immunology Authors: Katharine J. Foster, Emilio Jauregui, Bobby Tajudeen, Faraz Bishehsari, Mahboobeh Mahdavinia Tags: Letters Source Type: research

Reply
The article by Marco et  al1 titled “Asthmatic patients in COVID-19 outbreak: few cases despite many cases” discusses the prevalence of asthma in patients with coronavirus disease 2019 (COVID-19) in the Northeast of Italy. The low prevalence of asthma in patients with COVID-19 in Italy1 was consistent with what we obs erved in our study,2 but was much lower than those from the United States3 and Dublin.4 The reasons behind the regional difference in asthma with COVID-19 are worth discussion.
Source: Journal of Allergy and Clinical Immunology - June 21, 2020 Category: Allergy & Immunology Authors: Junqing Yue, Lu Qin, Cong Zhang, Min Xie Tags: Correspondence Source Type: research

Skull ‐base surgery during the COVID‐19 pandemic: the Italian Skull Base Society recommendations
AbstractSevere acute respiratory syndrome ‐coronavirus‐2 (SARS‐CoV‐2), which causes coronavirus disease 2019 (COVID‐19), is highly contagious with devastating impacts for healthcare systems worldwide. Medical staff are at high risk of viral contamination and it is imperative to know what personal protective equipment (PPE) is appr opriate for each situation. Furthermore, elective clinics and operations have been reduced in order to mobilize manpower to the acute specialties combating the outbreak; appropriate differentiation between patients who require immediate care and those who can receive telephone consultat...
Source: International Forum of Allergy and Rhinology - June 14, 2020 Category: Allergy & Immunology Authors: Paolo Castelnuovo, Mario Turri ‐Zanoni, Apostolos Karligkiotis, Paolo Battaglia, Fabio Pozzi, Davide Locatelli, the Italian Skull Base Society Board, Italian Skull Base Society Board (Società Italiana Basicranio [SIB]), Claudio Bernucci, Mauriz Tags: REVIEW ARTICLE Source Type: research

Pages: 1  2